From the prognostic point of view, a significantly shorter median overall survival (OS) was observed among MDS cases which displayed lower percentages of proliferating non-lymphoid CD34+ precursors (p = 0.005) and NRBC (p<0.001), thrombocytopenia (p<0.001), ≥2 cytopenias (p = 0.02), increased serum LDH (p = 0.004), transfusion dependency (p = 0.01) and higher IPSS and WPSS scores (p<0.001). The gene discussed is CD34; the disease is myelodysplastic syndrome.